Crucell, BIOA&D form agreement to develop ceNOS technology

By Lisa Kerner

Erie, Pa., May 22 - Crucell NV signed a pair of licensing agreements with Korean biopharmaceutical company BIOA&D Co. Ltd. for the use of Crucell's PER.C6 technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of cardiovascular disease and for the use of the company's patented ceNOS gene therapy technology.

Under the agreement, BIOA&D will pay to Crucell a signing fee, annual maintenance fees and milestone payments. Additional financial details were not disclosed.

Located in Leiden, The Netherlands, Crucell specializes in vaccines and antibodies that prevent and treat infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.